Feasibility, Adoption and Efficacy of A Virtual Reality Smoking Cessation Program for Patients Undergoing Lung Cancer Screening
Launched by CEDARS-SINAI MEDICAL CENTER · Aug 28, 2023
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people quit smoking by using virtual reality (VR) technology. It focuses on patients who are undergoing lung cancer screening and may not want to or be able to use traditional medications to stop smoking. The trial aims to see if VR can effectively support these individuals in overcoming their cravings to smoke, especially since many people find it hard to quit without some form of help. By using a method called "cue exposure therapy," the VR program will expose participants to situations that trigger their cravings and teach them ways to manage those urges.
To be eligible for this study, participants need to be adults aged 50 to 80 who are at high risk for lung cancer and currently smoke. They should also be able to read and understand the consent forms and have access to a smartphone that can run the VR app. However, people with certain medical conditions, like photosensitive epilepsy, or those who are not fluent in English or Spanish will not be able to participate. If you join the trial, you can expect to engage in VR sessions designed to help you quit smoking, with the hope that this innovative approach will make it easier for you to break free from tobacco use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to read and understand informed consent
- • Easy access to personal smartphone o Male or female adults who are at high risk for lung cancer and are enrolled in the Cedars-Sinai lung cancer screening program A: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke B: Based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited
- Exclusion Criteria:
- • Persons with photosensitive epilepsy will be excluded; flashing scenes in the virtual reality can trigger seizures.
- • Any records flagged "break the glass" or "research opt-out."
- • Persons who are unable to use smart phone or have a smartphone that is not compatible with a virtual reality app. The app is currently available in English and Spanish, and those who are not fluent in speaking and reading English or Spanish are excluded from the study.
About Cedars Sinai Medical Center
Cedars-Sinai Medical Center is a renowned nonprofit academic medical center located in Los Angeles, California, recognized for its commitment to patient care, research, and education. As a leading institution in clinical trials, Cedars-Sinai harnesses innovative approaches to advance medical knowledge and improve treatment outcomes across various specialties. With a multidisciplinary team of experts, state-of-the-art facilities, and a patient-centered approach, Cedars-Sinai actively contributes to the development of novel therapies and interventions, ensuring the highest standards of clinical research while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported